RATIONALE: The development of chronic obstructive pulmonary disease (COPD) in smokers and their susceptibility to infections is not fully understood. Recent evidences suggest that Clara cells play a part in host defense, immunomodulatory response and airways remodelling through the production of specific factors such as Clara cell 16 (CC-16). This protein has never been related to patients' lung function tests, blood gases parameters and diseases severity. OBJECTIVES: To evaluate a possible correlation between CC-16 expression in sputum, measured by a new methodological approach, and the degree of severity in patients with moderate and severe COPD. We also analyzed possible correlations between CC-16 and cytological sputum population, arterial blood gases and lung function. MAIN FINDINGS: We analyzed 20 patients, mean age 72.95, classified on the basis of the global initiative for chronic obstructive lung disease guidelines (GOLD 2006). The samples were processed for cytological analysis and CC-16 levels were assessed by Western blot. We found lower levels of CC-16 in severe COPD compared to moderate ones (p<0.027). No statistically significant differences were found between CC-16 expression and sputum cellularity (except for macrophages), arterial blood gases, and spirometric parameters. Multiple linear regression analysis of CC-16 versus functional and cytological parameters showed no significance. CONCLUSIONS: We found a significantly different expression of CC-16 in COPD patients, according to their stage of severity, as defined by the GOLD 2006 guidelines. Considering CC-16 properties in innate immunity, a possible link between protein expression, innate immune system, and COPD infectious exacerbations may be hypothesized but further investigation are needed.
RATIONALE: The development of chronic obstructive pulmonary disease (COPD) in smokers and their susceptibility to infections is not fully understood. Recent evidences suggest that Clara cells play a part in host defense, immunomodulatory response and airways remodelling through the production of specific factors such as Clara cell 16 (CC-16). This protein has never been related to patients' lung function tests, blood gases parameters and diseases severity. OBJECTIVES: To evaluate a possible correlation between CC-16 expression in sputum, measured by a new methodological approach, and the degree of severity in patients with moderate and severe COPD. We also analyzed possible correlations between CC-16 and cytological sputum population, arterial blood gases and lung function. MAIN FINDINGS: We analyzed 20 patients, mean age 72.95, classified on the basis of the global initiative for chronic obstructive lung disease guidelines (GOLD 2006). The samples were processed for cytological analysis and CC-16 levels were assessed by Western blot. We found lower levels of CC-16 in severe COPD compared to moderate ones (p<0.027). No statistically significant differences were found between CC-16 expression and sputum cellularity (except for macrophages), arterial blood gases, and spirometric parameters. Multiple linear regression analysis of CC-16 versus functional and cytological parameters showed no significance. CONCLUSIONS: We found a significantly different expression of CC-16 in COPDpatients, according to their stage of severity, as defined by the GOLD 2006 guidelines. Considering CC-16 properties in innate immunity, a possible link between protein expression, innate immune system, and COPD infectious exacerbations may be hypothesized but further investigation are needed.
Authors: Stefano Guerra; Marilyn Halonen; Monica M Vasquez; Amber Spangenberg; Debra A Stern; Wayne J Morgan; Anne L Wright; Iris Lavi; Lluïsa Tarès; Anne-Elie Carsin; Carlota Dobaño; Esther Barreiro; Jan-Paul Zock; Jesús Martínez-Moratalla; Isabel Urrutia; Jordi Sunyer; Dirk Keidel; Medea Imboden; Nicole Probst-Hensch; Jenny Hallberg; Erik Melén; Magnus Wickman; Jean Bousquet; Danielle C M Belgrave; Angela Simpson; Adnan Custovic; Josep M Antó; Fernando D Martinez Journal: Lancet Respir Med Date: 2015-07-06 Impact factor: 30.700
Authors: Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea Journal: Respir Res Date: 2009-04-22
Authors: Deog Kyeom Kim; Michael H Cho; Craig P Hersh; David A Lomas; Bruce E Miller; Xiangyang Kong; Per Bakke; Amund Gulsvik; Alvar Agustí; Emiel Wouters; Bartolome Celli; Harvey Coxson; Jørgen Vestbo; William MacNee; Julie C Yates; Stephen Rennard; Augusto Litonjua; Weiliang Qiu; Terri H Beaty; James D Crapo; John H Riley; Ruth Tal-Singer; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2012-11-09 Impact factor: 21.405
Authors: Debra A Cockayne; Donavan T Cheng; Benjamin Waschki; Sriram Sridhar; Palanikumar Ravindran; Holly Hilton; Galina Kourteva; Hans Bitter; Sreekumar G Pillai; Sudha Visvanathan; Kai-Christian Müller; Olaf Holz; Helgo Magnussen; Henrik Watz; Jay S Fine Journal: PLoS One Date: 2012-06-12 Impact factor: 3.240
Authors: Neil R Hackett; Marcus W Butler; Renat Shaykhiev; Jacqueline Salit; Larsson Omberg; Juan L Rodriguez-Flores; Jason G Mezey; Yael Strulovici-Barel; Guoqing Wang; Lukas Didon; Ronald G Crystal Journal: BMC Genomics Date: 2012-02-29 Impact factor: 3.969
Authors: Pierachille Santus; Antonio Russo; Enzo Madonini; Luigi Allegra; Francesco Blasi; Stefano Centanni; Antonio Miadonna; Gianfranco Schiraldi; Sandro Amaducci Journal: Respir Res Date: 2012-10-18